IP portfolios: the five biggest headaches for in-house counsel

30-09-2019

IP portfolios: the five biggest headaches for in-house counsel

Jezper / Shutterstock.com

In-house counsel face daily challenges when managing and maintaining their IP portfolios. LSIPR asked two in-house counsel for the biggest challenges they face when managing and maintaining their IP portfolios. Here are the five things we learned.

1) Different patentability standards

In some countries it’s very difficult, if not impossible, to get claims that include ranges of sequence identity, warns Kamrin MacKnight, chief patent counsel at protein engineering company Codexis.

“We’re stuck with claims that cover only a specific sequence. That makes it much easier for competitors to design around our patents, as all they have to do is change one amino acid,” says MacKnight.


IP portfolios, patentability, amino acid, US Supreme Court, biotech, DNA, IP counsel, European Patent Office, USPTO, IPRs, inventions, litigation

LSIPR